



# ANUH PHARMA LTD.

3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI** - 400 018. **INDIA**  
Tel. : 91-22-6622 7575 • Fax : 91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

25<sup>th</sup> May, 2018

To,  
The Manager (Listing)  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Fort, Mumbai – 400001

**Sub: Submission of Audited Financial Results along with Auditor's Report  
for the year ended 31<sup>st</sup> March, 2018 & Declaration**

**Ref : Scrip Code No. 506260**

Dear Sir,

In continuation of our letter dated 25<sup>th</sup> May, 2018 and pursuant to the provisions of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following:

1. Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2018;
2. Auditor's Report on quarterly financial results and year to date results for the year ended 31<sup>st</sup> March, 2018; and
3. Declaration from Managing Director w.r.t. Audit Report with unmodified opinion to the Audited Financial Results for the financial year ended 31<sup>st</sup> March, 2018.

You are requested to kindly take note of the above.

Thanking you,

Yours faithfully,

For **Anuh Pharma Ltd**

*A.S. Ambrale*

**Ashwini Ambrale**  
**Company Secretary & Compliance Officer**  
(Membership No.: ACS 32456)



**Encl: As above**



**We Serve Since 1932**

Factory : E-17/3 & 17/4, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA Tel.: (02525) 605 361 / 605 362

**ANUH PHARMA LTD.**


CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018  
Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

**AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31<sup>st</sup> MARCH, 2018**

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended 31/03/2018	3 months ended 31/12/2017	3 months ended 31/03/2017	12 months ended 31/03/2018	12 months ended 31/03/2017
		Audited	Unaudited	Audited	Audited	Audited
I.	Revenue from operations (Refer note. 6)	6,709.76	6,332.91	5,710.59	24,123.59	21,695.40
II.	Other income (Refer note. 11)	154.34	156.87	235.27	738.98	759.07
III.	<b>Total Revenue (I + II)</b>	<b>6,864.10</b>	<b>6,489.78</b>	<b>5,945.86</b>	<b>24,862.57</b>	<b>22,454.47</b>
IV.	Expenses:					
	Cost of materials consumed	5,157.69	4,986.37	3,691.31	18,372.29	14,536.70
	Purchases of Stock-in-Trade	24.65	9.97	311.89	34.62	350.89
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(135.94)	(116.81)	(113.38)	(327.74)	173.79
	Employee benefits expense	260.93	217.52	236.25	900.11	721.54
	Finance costs	3.61	0.29	2.96	4.05	4.39
	Depreciation and amortization expense	52.15	44.37	52.30	183.15	196.79
	Excise duty (Refer note.6)	0.00	-	240.32	315.92	1,080.69
	Other expenses (Refer note.12)	1,020.22	679.39	742.52	3,038.46	2,631.08
	<b>Total expenses (IV)</b>	<b>6,383.31</b>	<b>5,821.10</b>	<b>5,164.17</b>	<b>22,520.86</b>	<b>19,695.87</b>
V.	<b>Profit / (Loss) before exceptional and items and tax (III - IV)</b>	<b>480.79</b>	<b>668.68</b>	<b>781.69</b>	<b>2,341.71</b>	<b>2,758.60</b>
VI.	Exceptional items	-	-	-	-	-
VII.	<b>Profit / (Loss) before tax (V - VI) (Refer note.4)</b>	<b>480.79</b>	<b>668.68</b>	<b>781.69</b>	<b>2,341.71</b>	<b>2,758.60</b>
VIII	Tax expense:					
	(1) Current tax	193.00	177.00	263.03	686.00	763.03
	(2) Deferred tax	(37.74)	(1.71)	(8.74)	4.47	(9.49)
		<b>155.26</b>	<b>175.29</b>	<b>254.29</b>	<b>690.47</b>	<b>753.54</b>
IX	<b>Profit/(Loss) after Tax (VII-VIII) (Refer note. 4)</b>	<b>325.53</b>	<b>493.39</b>	<b>527.40</b>	<b>1,651.24</b>	<b>2,005.06</b>
X	Other Comprehensive Income (net of Tax)					
	(i) Items that will not be reclassified to profit or loss	(5.25)	2.42	2.95	5.18	2.47
	(ii) Items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total Other Comprehensive Income (net of Tax)</b>	<b>(5.25)</b>	<b>2.42</b>	<b>2.95</b>	<b>5.18</b>	<b>2.47</b>
XI	<b>Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)</b>	<b>320.28</b>	<b>495.81</b>	<b>530.35</b>	<b>1,656.42</b>	<b>2,007.53</b>
	Paid up Equity Share Capital (Face value ₹ 5/- each)	1,252.80	1,252.80	1,252.80	1,252.80	1,252.80
	Other Equity (excluding revaluation reserves)				13,708.72	12,802.30
XII	Earnings per equity share (Non annualised) (In Rs.) (Refer note. 4)					
	(1) Basic	1.30	1.97	2.10	6.59	8.00
	(2) Diluted	1.30	1.97	2.10	6.59	8.00
See accompanying notes to the financial results						




*Handwritten signature*

Note-1

Statement of Assets and Liabilities

(Rs. in Lakhs)

PARTICULARS		As at March 31, 2018	As at March 31, 2017
<b>I</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current Assets</b>		
	(a) Fixed Assets		
	(i) Property, Plant and equipment	1,633.00	1,695.47
	(ii) Capital work-in-progress	591.83	25.84
	(iii) Intangible Assets	37.06	37.32
		2,261.89	1,758.63
	(b) Financial Assets		
	(i) Investments	3,069.57	3,113.07
	(ii) Loans and Advances	-	24.70
	(iii) Other Financial Assets	55.76	55.20
	(c) Deferred Tax Assets (Net)	114.48	121.68
	<b>Total Non-Current Assets</b>	<b>5,501.70</b>	<b>5,073.28</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	3,190.40	2,982.06
	(b) Financial Assets		
	(i) Investments	3,556.50	3,925.95
	(ii) Trade receivables	7,092.31	5,664.74
	(iii) Cash and cash equivalents	379.91	520.30
	(iv) Other Bank balances	420.40	118.75
	(v) Loans and Advances	43.04	42.88
	(vi) Other financial assets	213.30	143.74
	(c) Other current assets	521.69	397.95
	<b>Total Current Assets</b>	<b>15,417.55</b>	<b>13,796.37</b>
	<b>TOTAL ASSETS</b>	<b>20,919.25</b>	<b>18,869.65</b>
<b>I</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	(i) Equity Share Capital	1,252.80	1,252.80
	(ii) Other Equity	13,708.72	12,802.30
	<b>TOTAL EQUITY</b>	<b>14,961.52</b>	<b>14,055.10</b>
	<b>Liabilities</b>		
<b>1</b>	<b>NON-CURRENT LIABILITIES</b>		
	Provisions	94.83	72.70
	<b>TOTAL NON-CURRENT LIABILITIES</b>	<b>94.83</b>	<b>72.70</b>
<b>2</b>	<b>CURRENT LIABILITIES</b>		
	(a) Financial Liabilities		
	(i) Borrowings	244.38	-
	(ii) Trade Payables	5,198.38	4,218.30
	(iii) Other financial liabilities	246.36	223.39
	(b) Other current liabilities	44.21	181.35
	(c) Provisions	19.65	13.43
	(d) Current Tax Liabilities(Net)	109.92	105.38
	<b>TOTAL CURRENT LIABILITIES</b>	<b>5,862.90</b>	<b>4,741.85</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>20,919.25</b>	<b>18,869.65</b>



*Prasanna*

2. The results of the quarter & year ended 31<sup>st</sup> March, 2018 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 25<sup>th</sup> May, 2018.

3. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1<sup>st</sup> April, 2017, the Company has for the first time adopted Ind AS with a transition date of 1<sup>st</sup> April, 2016.

**4. Reconciliation of Net Profit and EPS as per Ind AS and IGAAP**

Particulars	12 months ended 31/03/2018	12 months ended 31/03/2017
<b>Profit before tax as per Ind AS ( as per above results)</b>	2,341.71	2,758.60
<b>Add/ less :-</b>		
<b>Mark to market loss/ (gain) on Investment in mutual funds</b>	222.25	(246.71)
<b>Employee benefit Ind AS</b>	-	(0.50)
<b>Profit before tax as per old IGAAP</b>	2,563.96	2,511.39
<b>Provision for Tax as per above results</b>	690.47	753.54
<b>Profit after Tax as per old IGAAP</b>	1,873.49	1,757.85
<b>Basic &amp; Diluted EPS (as per old IGAAP)</b>	7.48	7.02
<b>Basic &amp; Diluted EPS (as per Ind AS)</b>	6.59	8.00

5. The Board of Directors of the Company has recommended a final dividend of Rs.2.75/- per equity share of face value of Rs.5 /- each (i.e.55%), subject to shareholders' approval in the forthcoming 58<sup>th</sup> Annual General Meeting, as compared to previous year final dividend of Rs.2.50/- per equity share of face value of Rs.5 /- each (i.e.50%).

6. Revenue from operations for the period upto 30<sup>th</sup> June, 2017 are inclusive of excise duty in accordance with requirements of Ind AS. Effective from 01<sup>st</sup> July, 2017 with implementation of Goods and Service Tax (GST), the revenue from operation for the quarter ended 31<sup>st</sup> December, 2017 and 31<sup>st</sup> March, 2018 are exclusive of GST. Hence, the revenue from operations for the quarter and year ended 31<sup>st</sup> March, 2018 are not comparable with the amounts reported in the corresponding previous periods.

7. The figures for the quarter ended 31<sup>st</sup> March, 2018 and 31<sup>st</sup> March, 2017 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year.

8. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

*P. Prasad*



9. The reconciliation of net profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS for the Quarter and year ended 31<sup>st</sup> March, 2017 is given below:

PARTICULARS	(Rs. in Lakhs)	
	For the quarter ended 31/03/2017	For the year ended 31/03/2017
<b>Net Profit/(Loss) after Tax as per previous IGAAP</b>	<b>456.83</b>	<b>1,757.85</b>
Net Impact on Investments - Fair value option through P&L	72.90	250.97
Reclassification of net actuarial loss on employee defined benefit obligation	(3.59)	(5.78)
Impact of taxes in respect of the above adjustments	1.26	2.02
<b>Net Profit/(Loss) after Tax as per Ind AS</b>	<b>527.40</b>	<b>2,005.06</b>
<b>Other Comprehensive Income</b>		
Reclassification of net actuarial loss on employee defined benefit obligation (net of tax)	2.95	2.47
<b>Total Comprehensive Income for the period</b>	<b>530.35</b>	<b>2,007.53</b>

10. The reconciliation of Equity in accordance with Indian GAAP and Ind AS as at 31st March, 2017 is given below:

Particulars	(Rs. in Lakhs)	
	As at 31/03/2017	As at 01/04/2016
<b>Total Equity (Shareholder's funds) under previous GAAP</b>	<b>13,674.77</b>	<b>11,927.79</b>
<b>Ind AS Adjustments</b>		
Measurement of investments at fair value	377.86	130.66
Reversal of provision for proposed dividend including tax thereon	-	152.45
Others	2.47	
<b>Total Equity (Shareholder's funds) under Ind AS</b>	<b>14,055.10</b>	<b>12,210.90</b>

11. Other Income includes mark to market gain on investment (As per Ind AS) is as follows:

Particulars	Amount (Rs. In lakhs)
For 3 months ended 31/12/2017	87.22
For 3 months ended 31/03/2017	68.64
For 12 months ended 31/03/2017	246.71

12. Other Expenses includes mark to market loss on investment(As per Ind AS) is as follows:

Particulars	Amount (Rs. In lakhs)
For 3 months ended 31/03/2018	86.04
For 12 months ended 31/03/2018	222.25


13. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Limited

*Bipin N. Shah*

**Bipin N. Shah**  
Managing Director

(DIN: 00083244)



Place : Mumbai

Dated : 25<sup>th</sup> May, 2018

**Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**


**To**  
**The Board of Directors of**  
**Anuh Pharma Limited**

1. We have audited the accompanying statement of financial results of Anuh Pharma Limited ('the Company') for the quarter and year ended 31<sup>st</sup> March , 2018 (' the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation'), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 ('the Circular'). The financial results for the quarter and year ended 31<sup>st</sup> March, 2018 have been prepared on the basis of the financial results for the nine-month period ended 31<sup>st</sup> December, 2017, the audited annual financial statements as at and for the year ended 31<sup>st</sup> March, 2018, and the relevant requirements of the Regulation and the Circular, which are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these financial results based on our review of the financial results for the nine-month period ended 31<sup>st</sup> December, 2017 which was prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 Interim Financial Reporting specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended 31<sup>st</sup> March, 2018; and relevant requirements of the Regulation and the Circular.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed in financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date results:
  - i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, in this regard; and
  - ii. gives a true and fair view in conformity with the Ind-AS and other accounting principles generally accepted in India of the profit including other comprehensive income and other financial information of the Company for the quarter and year ended 31<sup>st</sup> March, 2018.



4. Further, read with paragraph 1 above, we report that the figures for the quarter ended 31<sup>st</sup> March, 2018 represent the derived figures between the audited figures in respect of the financial year ended 31<sup>st</sup> March, 2018 and the published year-to-date figures up to 31<sup>st</sup> December, 2017, being the date of the end of the third quarter of the current financial year, which were subjected to a limited review, as required under the Regulation and the Circular.

For JAYANTILAL THAKKAR & CO.  
CHARTERED ACCOUNTANTS  
(FIRM REG. NO. 104133W)



PLACE: Mumbai  
DATE: 25<sup>th</sup> May, 2018

*V. A. Merchant*

VIRAL A. MERCHANT  
PARTNER  
MEMBERSHIP NO. 116279



# ANUH PHARMA LTD.

3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI** - 400 018. **INDIA**  
Tel. : 91-22-6622 7575 • Fax : 91-22-6622 7600 / 7500  
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

25<sup>th</sup> May, 2018

To,  
The Manager (Listing)  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Fort, Mumbai – 400001

**Sub: Declaration w.r.t. Audit Report with unmodified opinion to the Audited Financial Results for the financial year ended 31<sup>st</sup> March, 2018**

**Ref : Scrip Code No. 506260**

Dear Sir,

With reference to the captioned subject and pursuant to the provisions of Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and in compliance with SEBI Circular CIR/CFD/CMD/56/2016 dated 27<sup>th</sup> May, 2016, we hereby declare that the Statutory Auditors of the Company i.e. Jayantilal Thakkar & Co., Chartered Accountants, have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company for the financial year ended 31<sup>st</sup> March, 2018.

You are requested to kindly take the same on record.


Thanking you,

Yours faithfully,

For **Anuh Pharma Ltd.**

*Bipin Shah*

**Bipin Shah**  
**Managing Director**  
**(DIN: 00083244)**



**We Serve Since 1932**

Factory : E-17/3 & 17/4, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA Tel.: (02525) 605 361 / 605 362